利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

85 条记录 (耗时 0.056 秒)

    Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
    31.
    发明授权
    Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 有权
    使用不抑制CD80与CTLA-4结合的抗CD80抗体治疗B细胞淋巴瘤

    公开(公告)号：US07153508B2

    公开(公告)日：2006-12-26

    申请号：US10073138

    申请日：2002-02-13

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/00 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
    33.
    发明申请
    Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma 审中-公开
    联合应用抗细胞因子抗体或拮抗剂和抗CD20治疗B细胞淋巴瘤

    公开(公告)号：US20050180975A1

    公开(公告)日：2005-08-18

    申请号：US11085014

    申请日：2005-03-21

    申请人： Nabil Hanna

    发明人： Nabil Hanna

    IPC分类号： A61K45/00 ,  A61K31/4745 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K38/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K16/24 ,  A61K31/203 ,  A61K31/7072

    CPC分类号： C07K16/244 ,  A61K38/00 ,  A61K39/39541 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/24 ,  A61K2300/00

    摘要： The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN®.

    摘要翻译： 本发明公开了用于治疗血液恶性肿瘤（包括B细胞淋巴瘤和白血病或固体非血液学肿瘤）的组合疗法，其包括施用抗细胞因子抗体或拮抗剂以抑制细胞因子的活性，所述细胞因子在B细胞的活化中起作用 。 这种抗体和拮抗剂，特别是抗IL10抗体和拮抗剂的施用对于避免或降低血液恶性细胞或固体肿瘤细胞对化学治疗剂和抗CD20或抗-CD22抗体的抗性特别有用。 本发明还提供了具有B细胞参与的实体瘤的组合疗法，包括施用抗细胞因子抗体和B细胞消耗抗体如RITUXAN。

    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS
    39.
    发明申请
    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 失效
    识别某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用

    公开(公告)号：US20090010939A1

    公开(公告)日：2009-01-08

    申请号：US11840593

    申请日：2007-08-17

    申请人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： C07K16/18

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。